Back to News
Market Impact: 0.25
Lupin Gets FDA Approval For Modafinil Tablets
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsProduct Launches
Lupin Limited received FDA approval for its Modafinil Tablets USP through an ANDA for the 100 mg and 200 mg strengths. The approval supports its ability to market a generic modafinil product in the U.S., which is a positive near-term fundamental development. Financial impact is not quantified in the article, but regulatory clearance typically improves revenue visibility versus a pending status.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Zoom and big financial firms add ‘Proof of Human’ badges from Sam Altman’s World to stop fraud and deep fakes
- Daiichi Life Offers to Buy Remainder of Australia’s Challenger